Latest Conference Articles

Phase 3 data presented at AAD 2026 show once-daily oral therapy clears skin as early as week 4, offering a fast-acting option for patients.

This portion of the AMETHYST trial is the second successful phase 2 study of litifilimab, an investigational monoclonal antibody for CLE.

Late-breaking data shared at AAD 2026 supports oral TYK2 envudeucitinib's efficacy and safety in moderate-to-severe plaque psoriasis.

At AAD 2026, Christopher Bunick, MD, PhD, and Patrick Burnett, MD, PhD, discuss late-breaking data of roflumilast cream's improvements in infants with AD.

Pelage’s PP405 novel topical reawakens dormant follicle stem cells, showing signs of terminal regrowth and fueling late-stage alopecia research.

Late-breaking phase 2 findings presented at AAD show nemolizumab achieved high EASI-90 rates and rapid itch relief in pediatric patients with atopic dermatitis.

Catch up on coverage from the first day of the 2026 American Academy of Dermatology Annual Meeting held in Denver, Colorado.

Nicole Negbenebor, MD, highlights the clinical and professional impact of community-driven education and evidence-based focus in skin of color dermatology.

Christopher Bunick, MD, PhD, interviews medical student Sabine Obagi on the value of conference participation, mentorship, and early exposure for aspiring dermatology clinicians at AAD 2026.

This year’s AAD poster awards highlight studies advancing skin cancer prevention, inflammatory disease management, and complex dermatology care.

BE HEARD extension data underscore the importance of early diagnosis and treatment initiation to optimize long-term outcomes in hidradenitis suppurativa.

With 80% of trial participants being children, this analysis provides some of the most robust early-response data available for a non-steroidal topical in pediatric AD.

Read more on how to navigate all the opportunities at this year’s AAD meeting, which starts today in Denver, Colorado.

At the pre-AAD meeting, Regina Benjamin, MD, MBA, discussed the role of clinicians as leaders in addressing social determinants of health, emphasizing prevention, education, and culturally responsive care.

These leaders are shaping the future of dermatology through their clinical expertise, research, and educational presentations.

Targeted therapies are increasingly used earlier in treatment rather than being reserved for severe or refractory cases.

Overall, the future of dermatology lies in integrating innovation with individualized, evidence-based, and patient-centered care.

PANP360 Immersive will deliver one-day, high-yield dermatology CME for NPs and PAs, featuring hands-on workshops, complex case strategies, and practical tips to optimize therapies.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.

Omar Noor, MD, FAAD, discusses strategies to improve psoriasis care for patients facing adherence challenges related to lifestyle or cognitive barriers.

Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP, reviewed clinical trial and long-term data supporting biologic therapies for HS, emphasizing individualized patient selection and timing of intervention.

Douglas DiRuggiero, DMSc, MHS, PA-C, reviewed clinical cases highlighting the distinct roles of topical ruxolitinib, tapinarof, and roflumilast in managing itch, inflammation, and long-term disease control in atopic dermatitis.

Douglas DiRuggiero, DMSc, MHS, PA-C, emphasized that relying solely on body surface area underestimates psoriasis burden, particularly for patients with disease in high-impact or special areas.

Catch up on coverage from this year's Winter Clinical Miami meeting.

Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP, highlighted that CHE is often mischaracterized and frequently involves overlapping subtypes.

At Winter Clinical Miami 2026, Andrew F. Alexis, MD, MPH, shares skin-of-color therapy pearls as Clay Cockerell, MD, spotlights must-biopsy mimickers.

Winter Clinical Miami experts shared professional development tips and clinical pearls during the meeting's classic "15 Tips in 15 Minutes" session.

Omar Noor, MD, shares pearls on type 2 inflammation, including dupilumab insights for atopic dermatitis, prurigo nodularis, and CSU at Horizons in Advanced Practice.